Sulfasalazine has 47 known drug interactions based on U.S. FDA drug labeling data. Of these, 1 are contraindicated combinations that should be avoided entirely. 30 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Sepiapterin, Articaine Hydrochloride And Epinephrine, Articaine Hydrochloride And Epinephrine Bitartrate. Patients taking Sulfasalazine should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 47
- Contraindicated
- 1
- Major
- 30
- Moderate
- 15
Contraindicated (1)
- Sulfasalazine + Sepiapterin— Sepiapterin reductase (SR) inhibitor that may reduce sepiapterin metabolism to BH4. Avoid concomitant use.
Major (30)
- Sulfasalazine + Articaine Hydrochloride And Epinephrine— Increased risk of methemoglobinemia when concurrently exposed to articaine.
- Sulfasalazine + Articaine Hydrochloride And Epinephrine Bitartrate— Increased risk of developing methemoglobinemia when concurrently exposed to this agent.
- Sulfasalazine + Benzocaine, Butamben, And Tetracaine Hydrochloride— Increased risk of methemoglobinemia when concurrently exposed to this sulfa drug oxidizing agent with local anesthetics.
- Sulfasalazine + Bupivacaine And Meloxicam— Increased risk of methemoglobinemia when local anesthetics are used concomitantly with sulfasalazine.
- Sulfasalazine + Bupivacaine Hydrochloride— Increased risk of methemoglobinemia when concurrently exposed with bupivacaine.
- Sulfasalazine + Dexamethasone Sodium Phosphate, Lidocaine Hydrochloride, Povidine Iodine— Associated with increased methemoglobinemia risk when used with ropivacaine.
- Sulfasalazine + Lidocaine— Increased risk of methemoglobinemia when used concurrently with lidocaine.
- Sulfasalazine + Lidocaine 5%— May cause methemoglobinemia when used concomitantly with lidocaine patch 5%.
- Sulfasalazine + Lidocaine And Capsaicin— Drug that increases risk of methemoglobinemia when used concurrently with lidocaine and capsaicin patch.
- Sulfasalazine + Lidocaine And Prilocaine— Increased risk of methemoglobinemia when concurrently exposed.
- Sulfasalazine + Lidocaine Hydrochloride— Increased risk of methemoglobinemia when used concurrently with lidocaine hydrochloride.
- Sulfasalazine + Lidocaine Hydrochloride And Epinephrine Bitartrate— Associated with increased methemoglobinemia risk when used concurrently with local anesthetics.
- Sulfasalazine + Lidocaine Hydrochloride And Hydrocortisone Acetate— Increased risk of methemoglobinemia when local anesthetic is concurrently exposed to sulfa drugs.
- Sulfasalazine + Lidocaine Hydrochloride Monohydrate— Concurrent exposure increases risk of methemoglobinemia in patients administered local anesthetics.
- Sulfasalazine + Lidocaine Patch 5%— Increased risk of methemoglobinemia; drugs associated with methemoglobinemia when used with local anesthetics.
- Sulfasalazine + Lidocaine, Isopropyl Alcohol— Increased risk of methemoglobinemia when used with lidocaine.
- Sulfasalazine + Lidocaine, Menthol— Increased risk of methemoglobinemia when lidocaine is concurrently exposed to sulfa drugs.
- Sulfasalazine + Lidothol Patch— Increased risk of methemoglobinemia when local anesthetics are concurrently exposed to sulfa drugs.
- Sulfasalazine + Marcaine, Lidocaine, Kenalog, Povidone Iodine— Increased risk of methemoglobinemia when concurrently exposed.
- Sulfasalazine + Mepivacaine Hydrochloride— Concurrent exposure increases risk of methemoglobinemia in patients administered mepivacaine.
- Sulfasalazine + Mercaptopurine— May inhibit TPMT enzyme, increasing risk of myelosuppression when coadministered with mercaptopurine. Use lowest possibl…
- Sulfasalazine + Methotrexate— Patients receiving concomitant therapy with methotrexate and sulfasalazine should be closely monitored for possible incr…
- Sulfasalazine + Penicillin G Benzathine And Penicillin G Procaine— Increased risk of methemoglobinemia when penicillin is concurrently administered with sulfasalazine.
- Sulfasalazine + Prilocaine Hcl And Epinephrine— Increased risk of methemoglobinemia when prilocaine is concurrently exposed to sulfasalazine.
- Sulfasalazine + Prilocaine Hydrochloride— Increased risk of methemoglobinemia when used concurrently with prilocaine.
- Sulfasalazine + Ropivacaine Hydrochloride— Increased risk of developing methemoglobinemia when concurrently exposed to sulfasalazine.
- Sulfasalazine + Sofosbuvir, Velpatasvir, And Voxilaprevir— BCRP substrate whose exposure may be altered by velpatasvir and voxilaprevir inhibition. Coadministration is not recomme…
- Sulfasalazine + Triamcinolone Acetonide— Increased risk of methemoglobinemia when concurrently exposed.
- Sulfasalazine + Triethanolamine Salicylate— Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.
- Sulfasalazine + Trubrexa Patch Er— Increased risk of methemoglobinemia when used with Trubrexa Transdermal Patch.
Moderate (15)
- Sulfasalazine + Azathioprine— Aminosalicylate derivative inhibits TPMT enzyme. Concomitant use should be done with caution.
- Sulfasalazine + Bupivacaine— May increase risk of methemoglobinemia when concurrently exposed with bupivacaine.
- Sulfasalazine + Bupivacaine Hydrochloride And Epinephrine Bitartrate— Increased risk of methemoglobinemia when concurrently exposed.
- Sulfasalazine + Bupivacaine Hydrochloride With Dextrose— Increased risk of developing methemoglobinemia when concurrently exposed.
- Sulfasalazine + Digoxin— Reduced absorption of digoxin reported when administered concomitantly with sulfasalazine.
- Sulfasalazine + Eltrombopag— BCRP substrate; eltrombopag may increase exposure. Monitor closely for signs of excessive exposure.
- Sulfasalazine + Eltrombopag Olamine— BCRP substrate; monitor for excessive exposure and consider dose reduction if appropriate.
- Sulfasalazine + Etanercept— Concurrent use may result in mild decrease in mean neutrophil counts compared to monotherapy; clinical significance unkn…
- Sulfasalazine + Folic Acid— Reduced absorption of folic acid reported when administered concomitantly with sulfasalazine.
- Sulfasalazine + Lidocaine And Tetracaine— Drug that increases risk of methemoglobinemia when used concomitantly with lidocaine and tetracaine.
- Sulfasalazine + Marcaine, Kenalog, Povidone Iodine— Increased risk of methemoglobinemia when concurrently exposed with bupivacaine.
- Sulfasalazine + Prenatal Multivitamin Tablet And Combination Omega-3 Softgel/Mineral Capsule— Inhibits the absorption and metabolism of folic acid.
- Sulfasalazine + Riluzole— Hepatotoxic drug; riluzole-treated patients taking this may have increased risk for hepatotoxicity.
- Sulfasalazine + Thioguanine— Inhibits TPMT enzyme; should be administered with caution to patients receiving concurrent thioguanine therapy.
- Sulfasalazine + Vadadustat— Vadadustat may increase sulfasalazine exposure as a BCRP substrate. Monitor for adverse effects and reduce dosage if nee…